drugset / Trial / NCT07327697
A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2302 vs. Tezspire® in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blinded, controlled Phase 1 study to compare the pharmacokinetic, safety and immunogenicity of QL2302 versus Tezspire®（Tezepelumab） in healthy subjects after a single dose.
Timeline
- Start
- 2025-12-22
- Primary completion
- 2026-07
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QL2302 | Unknown | 210 mg | Subcutaneous |
| Comparator | Tezepelumab | Monoclonal antibody | 210 mg | Subcutaneous |
Indications
No indication recorded.